The accelerated approval pathway is commonly used for approval of oncology drugs in part due to the serious and life-threatening nature of cancer and because of available intermediate clinical endpoints likely to predict clinical benefit.
Tag Archive for: draft guidance
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) are combining their efforts to increase racial and ethnic diversity in clinical trials.
